Garcia-Aranda, MarilinaTellez, TeresaMcKenna, LauraineRedondo, Maximino2023-05-032023-05-032022-04-30García-Aranda M, Téllez T, McKenna L, Redondo M. Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance. Cancers (Basel). 2022 Apr 30;14(9):22552072-6694http://hdl.handle.net/10668/20890Nowadays, the identification of new therapeutic targets that allow for the development of treatments, which as monotherapy, or in combination with other existing treatments can contribute to improve response rates, prognosis and survival of oncologic patients, is a priority to optimize healthcare within sustainable health systems. Recent studies have demonstrated the role of Substance P (SP) and its preferred receptor, Neurokinin 1 Receptor (NK-1R), in human cancer and the potential antitumor activity of NK-1R antagonists as an anticancer treatment. In this review, we outline the relevant studies published to date regarding the SP/NK-1R complex as a key player in human cancer and also evaluate if the repurposing of already marketed NK-1R antagonists may be useful in the development of new treatment strategies to overcome cancer resistance.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/NK-1Rcancerdrug repurposingpersonalized medicineresistancetachykinintachykinin receptortargeted treatmentSubstance PReceptors, Neurokinin-1NeoplasmsDrug Resistance, NeoplasmTherapeutic Equivalency as TopicAntineoplastic Agents, Targetedreview35565383open accessSustancia PReceptores de Neuroquinina-1NeoplasiasAntagonistas de receptores de Neuroquinina-1Uso terapéutico de fármacosResistencia a fármacosMedicina personalizadaCáncer10.3390/cancers14092255PMC9102068https://www.mdpi.com/2072-6694/14/9/2255/pdf?version=1652100274https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102068/pdf